{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000158","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2022-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.234646+00:00","generated_at":"2026-06-27T10:25:37.529111+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS","bullets":["Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).","FY2021 net sales $1.186B (+5% YoY); diluted EPS $5.73 (-2% YoY); FX benefit $53.6M.","FY2022 guidance: net sales $1.125-$1.225B; diluted EPS $5.25-$6.00; expects net sales acceleration.","Q4 regional: Asia Pacific -15%, Americas/Europe -11%; COVID disruptions hurt key markets; Southeast Asia Pacific -26%.","Ended Q4 with $240M cash, no debt; repurchased 296K shares for $28.9M; $108M buyback remaining."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000158","json":"https://secwatch.observer/filing/0001157523-22-000158.json","markdown":"https://secwatch.observer/filing/0001157523-22-000158.md","text":"https://secwatch.observer/filing/0001157523-22-000158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/0001157523-22-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/a52576017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:25:37.529111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}